The US FDA has requested manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately.
A novel tetravalent dengue vaccine candidate developed by Takeda is found demonstrating similar degrees of protection in individuals who had and had not been previously infected with dengue.
Entacapone, the commonly used medication for Parkinson’s disease is not associated with increased risk of prostate cancer, said USFDA, confirming the safety of the drug in a recent announcement. In March 2010, the FDA warned the public about a possible risk of prostate cancer with the entacapone component of the product Stalevo, based on the […]
The European Medicines Agency (EMA) has recommended that the multiple sclerosis medicine fingolimod (Gilenya) must not be used in pregnant women and in women able to have children who are not using effective contraception. If a woman becomes pregnant while using fingolimod, the medicine must be stopped, and the pregnancy will have to be closely […]
Two drugs have emerged potential future treatments against Ebola virus demonstrating a cure rate of up to 90% in an ongoing clinical trial in the Democratic Republic of the Congo (DRC). The first-ever multi-drug randomized control trial, initiated by the WHO evaluated the safety and efficacy of four investigational agents – ZMapp, remdesivir, mAb114 and […]
The Union government has mooted a proposal to make it mandatory for all generic medicine manufacturers to print the generic names of drugs on the labels larger than the brand or trade names.
I had mentioned in my previous column that healthcare (not sick care) must be the focus of both policy and public. As I prepare to write this column, intending to focus on the theme of self-accountability for a healthy life,
Durvalumab and tremelimumab have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC).
EigerBio Pharmaceuticals Inc announced that the US FDA accepted the New Drug Application (NDA) for accelerated review of lonafarnib (Zokinvy) for the treatment of progeria and progeroid laminopathies.
